Company news

Enveric Biosciences, Inc. news in 2025

Enveric Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Enveric Biosciences Announces Patent Issuance

December 29, 2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

December 12, 2025

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

December 11, 2025

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

December 9, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"

December 4, 2025

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

November 26, 2025

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

November 14, 2025

Enveric Biosciences Announces Reverse Stock Split

October 23, 2025

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

October 16, 2025

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

October 15, 2025

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

October 14, 2025

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

October 2, 2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

September 18, 2025

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

September 17, 2025

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

September 17, 2025

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

September 16, 2025

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

September 2, 2025

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

August 28, 2025

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

August 14, 2025

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

July 23, 2025

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

July 15, 2025

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

June 24, 2025

Enveric Biosciences Announces Participation in 2025 BIO International Convention

June 16, 2025

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

June 10, 2025

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

June 3, 2025

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

March 31, 2025

Enveric Biosciences Participating in BIO-Europe Spring®

March 17, 2025

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

March 6, 2025

Enveric Biosciences CEO Issues Letter to Shareholders

February 27, 2025

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

February 25, 2025

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

February 3, 2025

Enveric Biosciences Announces Closing of $5 Million Public Offering

February 2, 2025

Enveric Biosciences Announces Pricing of $5 Million Public Offering

January 29, 2025

Decks in 2025